The proposed purchase of a portion of JB Chemicals and Pharmaceuticals by Torrent Pharmaceuticals Ltd. was approved by fair trade regulator CCI on 21 October, contingent on voluntary changes made by the parties. The move followed Torrent Pharmaceuticals’ announcement in June of this year that it would pay INR 19,500 crore to acquire the bulk of JB Chemicals and Pharmaceuticals.
In a statement, the regulator stated that the proposed combination is related to the acquisition of shares in JB Chemicals & Pharmaceuticals Ltd (target) by Torrent Pharmaceuticals Ltd (acquirer) and the subsequent merger of the target and the acquirer. Torrent Pharmaceuticals would be the second-most valuable pharmaceutical business in India if the deal is finalised.
Second Largest Deal in India’s Pharma Sector
Following Sun Pharmaceutical Industries’ 2015 acquisition of Ranbaxy Laboratories, this will be the second-biggest deal in the pharmaceutical industry history. JB Pharma will combine with Torrent following the acquisition of shares. For roughly INR 11,917 crore, Torrent announced in June that it would buy a 46.39% interest from promoters Tau Investment Holdings Pte Ltd, a division of the international investment group KKR.
Additionally, it would pay about INR 719 crore to purchase an additional 2.80% from specific JB Chemicals employees. Following this, it would make an open offer to purchase a 26% interest for INR 6,842.8 crore in accordance with Sebi’s listing requirements. The primary business of the Torrent group, Torrent Pharmaceuticals, manufactures and markets pharmaceutical formulations (FDFs) for a variety of therapeutic areas. In addition to producing and selling a wide variety of FDFs and active pharmaceutical ingredients (APIs), JB Chemicals and Pharmaceuticals also offers contract development and manufacturing organisation (CDMO) services.
In a post on X, the competition watchdog stated that the commission has approved Torrent Pharmaceuticals Ltd.’s acquisition of JB Chemicals & Pharmaceuticals Ltd. with voluntary changes. The Commission approved the proposed merger, the regulator added, provided that the parties (Torrent Pharmaceuticals Ltd. and JB Chemicals & Pharmaceuticals Ltd.) complied with the voluntary changes they presented.
Financial Dynamics of Torrent Pharma & JB Chemicals & Pharmaceuticals
KKR acquired a 65% share in JB Chemicals & Pharmaceuticals in 2020. Through open market transactions, KKR sold a 5.8% share in JB Pharma in March of this year for INR 1,460 crore. The cornerstone business of the Torrent Group, which generates INR 45,000 crore in total revenue annually, is Torrent Pharma, which generates around INR 11,500 crore. In an all-stock deal valued at USD 4 billion, including USD 800 million in debt, Sun Pharma announced in April 2014 that it will buy ailing rival Ranbaxy.
A year later, in March 2015, the merger was “consummated” once the necessary permissions were obtained. The acquisition of Bharat Serums and Vaccines by Mankind Pharma last year for INR 13,768 crore was another significant deal. In a different announcement, CCI authorised Setu AIF Trust, Konark Trust, and MMPL Trust to purchase a portion of Edelweiss Asset Management Ltd and Edelweiss Trusteeship Company Ltd.
According to the watchdog, Setu AIF Trust, Konark Trust, and MMPL Trust will acquire up to 15% of the shares in Edelweiss Asset Management Ltd (EAML) and Edelweiss Trusteeship Company Ltd (ETCL) as a result of the proposed combination’s interrelated processes. Setu AIF Trust is an alternative investment fund (AIF) that is registered with SEBI. Through MMPL, its investment manager, it takes action. ETCL serves as the trustee for Edelweiss Mutual Fund (EMF), while EAML manages the fund’s assets.
|
Quick Shots |
|
•CCI •Total •After •Torrent Pharma manufactures |